Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Clinical trial NCT00071838 · COMPLETED

Trial details

NCT number: NCT00071838
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2003-10-30
Primary completion: 2007-10-04
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.